Mydecine Innovations Group

Mydecine Innovations Group™ is a biotechnology company founded in 2020, with a mission to develop innovative first- and second-generation novel therapeutics for the treatment of mental health and addiction. The company's world-class technology and drug development infrastructure are supported by a world-renowned medical and scientific advisory board. They are focused on progressing a robust research and development (R&D) pipeline of psychedelic derived therapeutics, novel compounds, therapies, and controlled drug delivery systems.

With their slogan, "Reimagining Safer and More Effective Treatments for Mental Health and Addiction," Mydecine Innovations Group™ is positioned in the health care industry and headquartered in the United States. As of now, there is no publicly disclosed information regarding the company's last investment or the involved investors.

Overall, Mydecine Innovations Group™ presents an intriguing proposition in the biotechnology space, with a focus on addressing critical unmet needs in mental health and addiction treatment through innovative therapeutics and drug delivery systems.